Clinical Trial Update: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Clinical trial update on a Phase 3 study comparing Sacituzumab Govitecan-hziy to physician's choice in previously untreated locally advanced or metastatic tripl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Triple Negative Breast Cancer, PD-L1 Negative | Phase 3 | Status: ACTIVE_NOT_RECRUITING